RxDoctor Payments Data

Vasko Gulevski, MD

Neurology · Freehold, NJNPI 1528011517

Payments from drug & device makers

$23,682in general payments, 2019–2025

Across 1,598 payments — averaging $14.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$8K
  • Novartis$2K
  • Pfizer$1K
  • Teva Pharmaceuticals USA, Inc.$1K
  • EMD Serono, Inc.$1K
  • Lilly USA, LLC$1K
  • plus $8K from 54 others

What the payments were for

  • Speaking & faculty fees$4,93821%
  • Food & beverage$18,68279%
  • Education$620%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)356$8,253
Novartis146$1,537
Pfizer143$1,484
Teva Pharmaceuticals USA, Inc.140$1,480
EMD Serono, Inc.99$1,442
Lilly USA, LLC70$1,093
Biogen78$1,022
Supernus Pharmaceuticals, Inc.44$505
Biohaven Pharmaceutical Holding Company Ltd.57$466
AstraZeneca(2 entities)27$390
Lundbeck LLC29$368
Neurelis, Inc.24$355
Sunovion Pharmaceuticals Inc.24$335
Amgen(2 entities)27$302
Grifols USA, LLC19$287
Biohaven Pharmaceuticals, Inc.23$243
Kyowa Kirin, Inc.17$235
Axsome Therapeutics, Inc.17$235
Scilex Pharmaceuticals Inc.16$233
Upsher-smith Laboratories LLC11$218
Argenx US, Inc.13$197
Neos Therapeutics, LP19$196
Sumitomo Pharma America, Inc.15$184
Otsuka America Pharmaceutical, Inc.9$169
Eisai Inc.10$164
SK Life Science, Inc.11$154
Impel Pharmaceuticals Inc.16$146
UCB, Inc.9$130
Harmony Biosciences LLC8$124
Sanofi8$108
Adlon Therapeutics L.p.6$85
Merz North America, Inc.3$79
Johnson & Johnson(2 entities)6$78
Merz Pharmaceuticals, LLC5$76
Neurocrine Biosciences, Inc.5$75
Amneal Pharmaceuticals LLC5$69
W. L. Gore & Associates, Inc.5$68
Currax Pharmaceuticals LLC5$67
Takeda Pharmaceuticals U.S.A., Inc.5$67
Avanir Pharmaceuticals, Inc.5$67
Life Molecular Imaging Ltd5$66
Acorda Therapeutics, Inc5$65
Alnylam Pharmaceuticals Inc.4$63
Vanda Pharmaceuticals Inc.4$63
Mallinckrodt Hospital Products Inc.4$59
Adamas Pharmaceuticals, Inc.4$57
ANI Pharmaceuticals, Inc.3$48
Corium, LLC3$43
Portola Pharmaceuticals, LLC3$42
CSL Behring2$40
Almatica Pharma LLC3$40
Impel Pharmaceuticals LLC4$37
Tris Pharma Inc2$30
Collegium Pharmaceutical, Inc.2$30
Avion Pharmaceuticals2$28
Acadia Pharmaceuticals Inc2$26
E.r. Squibb & Sons, L.L.C.2$26
Ipsen Biopharmaceuticals, Inc2$25
Boston Scientific1$24
Tonix Medicines, Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,682 in reported general payments places this provider in the 75th percentile of 521 neurology providers in New Jersey.

See all neurology providers in New Jersey

Medicare billing

Part B allowed, 2024
$383,903
Medicare patients
653
Services billed
16,943

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UltomirisRavulizumab-Cwvz17$1,172,779
QuliptaAtogepant91$104,328
UbrelvyUbrogepant54$85,861
Nurtec OdtRimegepant Sulfate24$50,510
RexultiBrexpiprazole15$33,253
Aimovig AutoinjectorErenumab-Aooe23$20,005
Emgality PenGalcanezumab-Gnlm28$18,471
FycompaPerampanel11$15,590
BriviactBrivaracetam12$12,883
Keppra XrLevetiracetam12$11,831
Memantine Hcl269$11,609
OxycontinOxycodone Hcl13$10,640
Ajovy AutoinjectorFremanezumab-Vfrm14$10,047
AdlarityDonepezil Hcl11$4,983
Carbidopa-LevodopaCarbidopa/Levodopa135$4,196

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaUltomiris$390$1,172,77917 claims
AbbVieQulipta, Ubrelvy$8,253$190,189145 claims
PfizerNurtec Odt$1,484$50,51024 claims
Otsuka America Pharmaceutical, Inc.Rexulti$169$33,25315 claims
Eisai Inc.Fycompa$164$15,59011 claims
UCB, Inc.Briviact$130$12,88312 claims
Corium, LLCAdlarity$43$4,98311 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$69$99018 claims
Upsher-smith Laboratories LLCTopiramate$218$80344 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 521 neurology providers in New Jersey.

Other neurology in Freehold

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →